AKEBIA THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
AKEBIA THERAPEUTICS, INC. (AKBA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $5.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- AKEBIA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $5.80M, a 74.22% decline from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $22.50M, a 378.72% increase from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $4.70M, a 74.18% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $18.20M, a 71.65% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $5.80M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $22.50M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $4.70M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $18.20M 10-K · filed 2024-03-14 | $17.80M 10-K · filed 2023-03-10 |
| 2021-12-31 | $64.20M 10-K/A · filed 2023-08-28 | |
| 2020-12-31 | $82.50M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $64.00M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $23.30M 10-K · filed 2020-03-12 | |
| 2017-12-31 | -$4.90M 10-K · filed 2019-03-26 | |
| 2016-12-31 | $56.40M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $22.30M 10-K · filed 2017-03-06 | |
| 2014-12-31 | $13.80M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |